Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

PURPOSE: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Manag Res
Autori principali: Novakova-Jiresova, Alena, Kopeckova, Katerina, Boublikova, Ludmila, Chloupkova, Renata, Melichar, Bohuslav, Petruzelka, Lubos, Finek, Jindrich, Fiala, Ondrej, Grell, Peter, Batko, Stanislav, Linke, Zdenek, Kiss, Igor, Prausova, Jana, Buchler, Tomas
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7342462/
https://ncbi.nlm.nih.gov/pubmed/32753954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S255332
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi